XtalPi Holdings (2228) H1 2025 earnings summary

Executive summary

• Revenue surged 404% year-over-year in 1H25, reaching RMB 517.1mn, with the company achieving profitability for the first time on a half-year basis, driven by major drug discovery collaborations and robotics solutions.

• Adjusted net profit turned positive at RMB 142mn, compared to a loss of RMB 251mn in 1H24; net profit was RMB 75.6mn, reversing a RMB 1,237.6mn loss.

• Monthly average cash burn declined by 20% year-over-year to RMB 49.7mn, with a cash balance of RMB 5,308mn as of June 30, 2025, supporting operations for 8.9 years.

• Major strategic collaborations, technological advancements in AI and robotics, and inclusion in the MSCI China Small Cap Index drove business growth and recognition.

• R&D expenses rose 5% year-over-year to RMB 222mn, reflecting continued investment in innovation.

Financial highlights

• Revenue increased to RMB 517.1mn in 1H25 from RMB 102.6mn in 1H24, a 404% year-over-year rise; drug discovery solutions up 615.2% to RMB 435.2mn, robotics solutions up 95.9% to RMB 81.9mn.

• Cost of revenue increased 47.7% to RMB 82mn; general and administrative expenses decreased 14.5% to RMB 200.3mn.

• Operating profit reached RMB 32.7mn, reversing a RMB 392.9mn loss; finance income, net, rose 47.5% to RMB 48.2mn.

• Basic EPS was RMB 2.30 cents, diluted EPS RMB 2.20 cents.

• Cash balance increased 70% to RMB 5,308mn as of June 30, 2025, mainly due to new share placements.

Outlook and guidance

• Ongoing expansion of AI-driven platforms and strategic partnerships expected to sustain growth, leveraging AI, quantum physics, and automation.

• Sufficient working capital and strong cash position support long-term strategy and expansion.

• Continued focus on enhancing R&D efficiency and commercializing autonomous lab solutions across industries.